Q-omics provides the consensus-scored TCAP profile across patient tissues and cancer cell-line models. TCAP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TCAP is differentially expressed in 11, with the highest sampling consensus in STAD. Additionally, TCAP RNA expression shows 18,599 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, STAD, and ACC as cancer lineages where TCAP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCAP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCAP survival associations across molecular data types. TCAP RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCAP RNA expression–survival associations across cancer types. High TCAP expression shows unfavorable associations in KIRP, MESO, KIRC, ACC and COAD, but favorable associations in THYM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TCAP RNA expression.
This table summarizes TCAP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in STAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TCAP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCAP shows lower tumor expression in HNSC, LUAD and LUSC and higher tumor expression in STAD, COAD and LIHC. The STAD box plot shows higher TCAP RNA expression in tumor versus normal tissue (log2 FC = +0.608, t-test p < 0.001).
This table shows molecular features associated with TCAP in patient tissues and cancer cell lines. In patient samples, TCAP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TCAP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
